Pfizer buys Global Blood Therapeutics in a $5.4 billion deal

FILE – The Pfizer logo is placed on the exterior of a former Pfizer factory in the Brooklyn borough of New York, May 4, 2014. Pfizer is buying sickle-cell drugmaker Global Blood Therapeutics in a deal worth around $5.4 billion to accelerate growth after its revenues skyrocketed during the pandemic. The boards of directors of both companies have approved the transaction, which is subject to regulatory approval and GBT shareholder approval. (AP Photo/Mark Lennihan, file) (Mark Lennihan, Copyright 2022 The Associated Press. All rights reserved.)

Pfizer is buying sickle-cell drugmaker Global Blood Therapeutics in a deal worth around $5.4 billion to accelerate growth after its revenues skyrocketed during the pandemic.

GBT is the developer of Oxbryta tablets, which directly target the cause of sickle cell anemia. Oxbryta’s revenue last year was approximately $195 million.

Pfizer will pay $68.50 in cash for each GBT share.

The boards of directors of both companies have approved the transaction, which is subject to regulatory approval and GBT shareholder approval.


https://www.local10.com/business/2022/08/08/pfizer-buying-global-blood-therapeutics-in-54b-deal/ Pfizer buys Global Blood Therapeutics in a $5.4 billion deal

Sarah Y. Kim

InternetCloning is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@internetcloning.com. The content will be deleted within 24 hours.

Related Articles

Back to top button